Related Experiment Video
Updated: Jul 12, 2025
Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
Published on: November 15, 2024
Management of liver disease and portal hypertension in common variable immunodeficiency (CVID)
Lukas S Baumert1,2, Angela Shih3, Raymond T Chung1
1Liver Center, Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Insights
Common variable immunodeficiency (CVID) often causes liver disease, specifically nodular regenerative hyperplasia (NRH) leading to non-cirrhotic portal hypertension (NCPH). This review highlights diagnostic and management strategies for CVID-related liver complications.
Area of Science:
- Immunology
- Hepatology
- Gastroenterology
Background:
- Common variable immunodeficiency (CVID) is frequently associated with liver disease, a significant unmet medical need.
- Nodular regenerative hyperplasia (NRH) is the primary hepatic manifestation, causing non-cirrhotic portal hypertension (NCPH).
- Underdiagnosis and lack of specific guidelines contribute to poor patient outcomes.
Purpose of the Study:
- To review the epidemiology of CVID-related liver disease.
- To provide insights into NRH and NCPH biology and diagnostics.
- To outline current and future management strategies for CVID-associated liver disease and portal hypertension.
Main Methods:
- Literature review focusing on CVID, liver disease, NRH, and NCPH.
- Analysis of diagnostic opportunities for NCPH in CVID patients.
- Evaluation of current treatment modalities, including TIPS and liver transplantation.
- Discussion of potential therapeutic agents targeting NRH pathogenesis.
Main Results:
- CVID-related liver disease, particularly NRH/NCPH, is underdiagnosed and poorly managed.
- New diagnostic approaches for NCPH in CVID are emerging.
- Transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation are key management options.
- Anticoagulants and immunosuppressants may play a role in NRH treatment.
Conclusions:
- An updated diagnostic and treatment algorithm for NCPH in CVID is proposed.
- There is a critical need for improved clinical management and therapeutic strategies.
- Future research should focus on novel treatments for CVID-related liver disease.
Abstract:
Patients with common variable immunodeficiency (CVID) frequently develop liver disease and associated complications, which represent an increasingly prevalent unmet medical need. The main hepatic manifestation of CVID is nodular regenerative hyperplasia (NRH), resulting in non-cirrhotic portal hypertension (NCPH). Liver disease is often underdiagnosed, leading to poor outcomes and decreased survival. The increasing numbers of patients with CVID who are diagnosed late with progressive liver disease underscores the importance of appropriate clinical management and treatment of liver complications. At the same time, specific guidelines for the clinical management of CVID-related liver disease are still lacking. Here, we review the epidemiology of CVID-related liver disease, reveal new insights into NRH and NCPH biology and highlight recently uncovered opportunities for NCPH diagnostics in CVID. Finally, we focus on current management of liver disease, portal hypertension and its complications - the key challenge in patients with CVID. Specifically, we review recent data regarding the role of transjugular intrahepatic portosystemic shunt and liver transplantation in clinical management. The role for anticoagulants and immunosuppressants targeting the pathogenesis of NRH will also be discussed. We propose an updated algorithm for the diagnostic work-up and treatment of NCPH in CVID. Finally, we consider future needs and therapeutic opportunities for CVID-related liver disease.
Related Concept Videos
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:21Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...